Multiple Sclerosis Clinical Trial

Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)

Summary

The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.

View Full Description

Full Description

To study the effect of ocrelizumab on cortical lesion accumulation in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomized, phase 3, placebo-controlled study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient participating in the ORATORIO study
MRI scans available at baseline
Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 2D/3D T1-WI at baseline

Exclusion Criteria:

- None

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

732

Study ID:

NCT05974839

Recruitment Status:

Active, not recruiting

Sponsor:

State University of New York at Buffalo

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Buffalo Neuroimaging Analysis Center
Buffalo New York, 14203, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

732

Study ID:

NCT05974839

Recruitment Status:

Active, not recruiting

Sponsor:


State University of New York at Buffalo

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.